Trial · NCT03964415
Results by group130
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 130
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 24 Visits (Per-protocol [PP] Set) | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | 65 | Participants | ||
| Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 24 Visits (Per-protocol [PP] Set) | Group 2: Placebo | 58 | Participants | ||
| Number of Participants With a Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 30 Visits (PP Set) | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | 71 | Participants | ||
| Number of Participants With a Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 30 Visits (PP Set) | Group 2: Placebo | 67 | Participants | ||
| Number of Participants With Solicited Local Adverse Events (AEs) | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | Up to 7 days post dose on Day 1 | 1225 | Participants | |
| Number of Participants With Solicited Local Adverse Events (AEs) | Group 2: Placebo | Up to 7 days post dose on Day 1 | 329 | Participants | |
| Number of Participants With Solicited Local Adverse Events (AEs) | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | Up to 7 days post dose on Day 84 | 905 | Participants | |
| Number of Participants With Solicited Local Adverse Events (AEs) | Group 2: Placebo | Up to 7 days post dose on Day 84 | 239 | Participants | |
| Number of Participants With Solicited Local Adverse Events (AEs) | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | Up to 7 days post dose on Day 168 | 1010 | Participants | |
| Number of Participants With Solicited Local Adverse Events (AEs) | Group 2: Placebo | Up to 7 days post dose on Day 168 | 319 | Participants | |
| Number of Participants With Solicited Local Adverse Events (AEs) | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | Up to 7 days post dose on Day 364 | 917 | Participants | |
| Number of Participants With Solicited Local Adverse Events (AEs) | Group 2: Placebo | Up to 7 days post dose on Day 364 | 252 | Participants | |
| Number of Participants With Solicited Systemic Adverse Events (AEs) | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | Up to 7 days post dose on Day 1 | 1313 | Participants | |
| Number of Participants With Solicited Systemic Adverse Events (AEs) | Group 2: Placebo | Up to 7 days post dose on Day 1 | 860 | Participants | |
| Number of Participants With Solicited Systemic Adverse Events (AEs) | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | Up to 7 days post dose on Day 84 | 891 | Participants | |
| Number of Participants With Solicited Systemic Adverse Events (AEs) | Group 2: Placebo | Up to 7 days post dose on Day 84 | 572 | Participants | |
| Number of Participants With Solicited Systemic Adverse Events (AEs) | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | Up to 7 days post dose on Day 168 | 856 | Participants | |
| Number of Participants With Solicited Systemic Adverse Events (AEs) | Group 2: Placebo | Up to 7 days post dose on Day 168 | 535 | Participants | |
| Number of Participants With Solicited Systemic Adverse Events (AEs) | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | Up to 7 days post dose on Day 371 | 759 | Participants | |
| Number of Participants With Solicited Systemic Adverse Events (AEs) | Group 2: Placebo | Up to 7 days post dose on Day 371 | 432 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03964415/results